A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus

• Published in: Journal of the American College of Cardiology Vol. 52; no. 9; pp. 727 - 733
• Main Authors: Lee, Seung-Whan, MD, PhD, Park, Seong-Wook, MD, PhD, FACC, Kim, Young-Hak, MD, PhD, Yun, Sung-Cheol, PhD, Park, Duk-Woo, MD, PhD, Lee, Cheol Whan, MD, PhD, Hong, Myeong-Ki, MD, PhD, Rhee, Kyoung-Suk, MD, PhD, Chae, Jei Keon, MD, PhD, Ko, Jae-Ki, MD, PhD, Park, Jae-Hyeong, MD, PhD, Lee, Jae-Hwan, MD, PhD, Choi, Si Wan, MD, Jeong, Jin-Ok, MD, PhD, Seong, In-Whan, MD, PhD, Cho, Yoon Haeng, MD, PhD, Lee, Nae-Hee, MD, PhD, Kim, June Hong, MD, PhD, Chun, Kook-Jin, MD, Kim, Hyun-Sook, MD, PhD, Park, Seung-Jung, MD, PhD, FACC
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 26-08-2008; Elsevier Science; Elsevier Limited
• Subjects: Aged; Angina pectoris; Angioplasty; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Biological and medical sciences; Blood Vessel Prosthesis Implantation; Cardiology; Cardiology. Vascular system; Cardiovascular; Clinical outcomes; Cohort Studies; coronary artery disease; Coronary Stenosis - diagnostic imaging; Coronary Stenosis - etiology; Coronary Stenosis - therapy; Diabetes Complications - complications; Diabetes Complications - diagnostic imaging; Diabetes Complications - therapy; diabetes mellitus; Diabetes. Impaired glucose tolerance; Drug-Eluting Stents; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Graft Occlusion, Vascular - prevention & control; Heart attacks; Humans; Immunosuppressive Agents - administration & dosage; Internal Medicine; Male; Medical sciences; Middle Aged; Paclitaxel - administration & dosage; paclitaxel-eluting stent; Pharmacology. Drug treatments; Radiography; Sirolimus - administration & dosage; sirolimus-eluting stent; Stents; Treatment Outcome; Tubulin Modulators - administration & dosage; Korea; coronary artery disease; major adverse cardiac events; RR; SES; MLD; myocardial infarction; sirolimus-eluting stent(s); DM; diabetes mellitus; interquartile range; drug-eluting stent(s); TVR; MACE; target vessel revascularization; TLR; MI; AMI; bare-metal stent(s); sirolimus-eluting stent; target lesion revascularization; paclitaxel-eluting stent; CI; BMS; IQR; minimal lumen diameter; QCA; relative risk; quantitative coronary angiography; DES; paclitaxel-eluting stent(s); confidence interval; acute myocardial infarction; PES; Endocrinopathy; Antineoplastic agent; Human; Sirolimus; Diabetes mellitus; Implantation; Antibiotic; Randomization; Paclitaxel; Circulatory system; Immunosuppressive agent; Antibacterial agent; Cardiology; Drug eluting stent; Comparative study
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2008.04.056

A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus Seung-Whan Lee, Seong-Wook Park, Young-Hak Kim, Sung-Cheol Yun, Duk-Woo Park, Cheol Whan Lee, Myeong-Ki Hong, Kyoung-Suk Rhee, Jei Keon Chae, Jae-Ki Ko, Jae-Hyeong Park, Jae-Hwan Lee, Si Wan Choi, Jin-Ok Jeong, In-Whan Seong, Yoon Haeng Cho, Nae-Hee Lee, June Hong Kim, Kook-Jin Chun, Hyun-Sook Kim, Seung-Jung Park To compare the effectiveness of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES), we randomly compared SES (n = 200) and PES (n = 200) in patients with diabetes mellitus (DM). Six-month in-stent (3.4% vs. 18.2%, p < 0.001) and in-segment restenosis (4.0% vs. 20.8%, p < 0.001) and 9-month target lesion revascularization (2.0% vs. 7.5%, p = 0.017) were significantly lower in the SES versus the PES group. Major adverse cardiac events including death, myocardial infarction, and target lesion revascularization at 9 months (2.0% vs. 8.0%, p = 0.010) were lower in the SES versus the PES group. In conclusion, SES significantly reduced angiographic restenosis and improved clinical outcomes in diabetic patients compared with PES implantation.